Actively Recruiting

Age: 18Years +
All Genders
ID05667948

Molecular Landscape Analysis and Treatment Options for Thymic Epithelial Tumors

Led by Shanghai Chest Hospital · Updated on 2025-05-22

500

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Thymic malignancies, including thymic epithelial tumors and carcinomas, are the most common tumors in the front part of the chest. While surgery and radiation can often treat these cancers, some cases continue to worsen and can be fatal. Researchers recognize the urgent need to better understand molecular changes in these tumors to predict how patients will respond to new targeted treatments and improve survival outcomes. This project is an observational study aiming to build a registry of patients with thymic malignancies to analyze their genetic alterations. Based on molecular analysis, different chemotherapy treatments may be evaluated. The study is focused on characterizing these molecular changes and exploring novel treatment approaches tailored to individual tumor profiles. Participants will be followed for up to 20 years to measure outcomes such as objective response rate, disease control rate, and progression-free survival. Overall survival will also be assessed. Throughout the study, patient information and treatment responses will be collected to advance molecular diagnostics and individualized care for thymic malignancies.

CONDITIONS

Brief Title

Molecular Analysis and Treatment Options of Thymic Malignancies

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically proven diagnosis of thymic malignancies
  • 18 years of age or older
  • Ability to understand and the willingness to sign a written informed consent document
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Varies according to treatment plan

Participants receive chemotherapy treatments tailored based on molecular analysis of their thymic malignancies.

Visit frequency depends on chemotherapy schedule

Long-term Monitoring

Duration - Up to 20 years

Participants are followed for up to 20 years to monitor treatment response and survival outcomes.

Periodic visits for assessments over 20 years

Trial Site Locations

Total: 1 location

1

Xiaomin Niu

Shanghai, Shanghai Municipality, China, 200030

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

Artificial Intelligence for Histopathological Classification...

Thymic Epithelial Tumor

Actively Recruiting

1 location

Clinical Study of CD70-Targeted CAR-T Therapy in Advanced CD...

Renal Cell Carcinoma (RCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here